Barely Significant
← all excerpts

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Front Immunol · 2021 · PMC8581537 · PMID 34777337

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantp<0.001actually significant
The greater levels of inhibition of proliferation increased with time on alemtuzumab and were highly significant (p<0.001; one-way ANOVA).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.